Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-099697
Filing Date
2024-11-18
Accepted
2024-11-18 17:01:27
Documents
69
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0220737-10q_aditxt.htm   iXBRL 10-Q 2252115
2 CERTIFICATION ea022073701ex31-1_aditxt.htm EX-31.1 10259
3 CERTIFICATION ea022073701ex31-2_aditxt.htm EX-31.2 10527
4 CERTIFICATION ea022073701ex32-1_aditxt.htm EX-32.1 4568
  Complete submission text file 0001213900-24-099697.txt   11712232

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE adtx-20240930.xsd EX-101.SCH 91479
6 XBRL CALCULATION FILE adtx-20240930_cal.xml EX-101.CAL 40405
7 XBRL DEFINITION FILE adtx-20240930_def.xml EX-101.DEF 483991
8 XBRL LABEL FILE adtx-20240930_lab.xml EX-101.LAB 823063
9 XBRL PRESENTATION FILE adtx-20240930_pre.xml EX-101.PRE 499199
72 EXTRACTED XBRL INSTANCE DOCUMENT ea0220737-10q_aditxt_htm.xml XML 1264716
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39336 | Film No.: 241472247
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)